• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂质组学在肺动脉高压诊断和预后评估中的应用

Lipidomics for diagnosis and prognosis of pulmonary hypertension.

作者信息

Bordag Natalie, Nagy Bence Miklos, Zügner Elmar, Ludwig Helga, Foris Vasile, Nagaraj Chandran, Biasin Valentina, Bodenhofer Ulrich, Magnes Christoph, Maron Bradley A, Ulrich Silvia, Lange Tobias J, Hötzenecker Konrad, Pieber Thomas, Olschewski Horst, Olschewski Andrea

机构信息

Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.

Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.

出版信息

medRxiv. 2023 Nov 29:2023.05.17.23289772. doi: 10.1101/2023.05.17.23289772.

DOI:10.1101/2023.05.17.23289772
PMID:37292870
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10246148/
Abstract

BACKGROUND

Pulmonary hypertension (PH) poses a significant health threat with high morbidity and mortality, necessitating improved diagnostic tools for enhanced management. Current biomarkers for PH lack functionality and comprehensive diagnostic and prognostic capabilities. Therefore, there is a critical need to develop biomarkers that address these gaps in PH diagnostics and prognosis.

METHODS

To address this need, we employed a comprehensive metabolomics analysis in 233 blood based samples coupled with machine learning analysis. For functional insights, human pulmonary arteries (PA) of idiopathic pulmonary arterial hypertension (PAH) lungs were investigated and the effect of extrinsic FFAs on human PA endothelial and smooth muscle cells was tested .

RESULTS

PA of idiopathic PAH lungs showed lipid accumulation and altered expression of lipid homeostasis-related genes. In PA smooth muscle cells, extrinsic FFAs caused excessive proliferation and endothelial barrier dysfunction in PA endothelial cells, both hallmarks of PAH.In the training cohort of 74 PH patients, 30 disease controls without PH, and 65 healthy controls, diagnostic and prognostic markers were identified and subsequently validated in an independent cohort. Exploratory analysis showed a highly impacted metabolome in PH patients and machine learning confirmed a high diagnostic potential. Fully explainable specific free fatty acid (FFA)/lipid-ratios were derived, providing exceptional diagnostic accuracy with an area under the curve (AUC) of 0.89 in the training and 0.90 in the validation cohort, outperforming machine learning results. These ratios were also prognostic and complemented established clinical prognostic PAH scores (FPHR4p and COMPERA2.0), significantly increasing their hazard ratios (HR) from 2.5 and 3.4 to 4.2 and 6.1, respectively.

CONCLUSION

In conclusion, our research confirms the significance of lipidomic alterations in PH, introducing innovative diagnostic and prognostic biomarkers. These findings may have the potential to reshape PH management strategies.

摘要

背景

肺动脉高压(PH)对健康构成重大威胁,发病率和死亡率都很高,因此需要改进诊断工具以加强管理。目前用于PH的生物标志物缺乏功能性以及全面的诊断和预后能力。因此,迫切需要开发能够填补PH诊断和预后这些空白的生物标志物。

方法

为满足这一需求,我们对233份血液样本进行了全面的代谢组学分析,并结合机器学习分析。为了获得功能方面的见解,我们研究了特发性肺动脉高压(PAH)患者肺部的人肺动脉(PA),并测试了外源性游离脂肪酸(FFA)对人PA内皮细胞和平滑肌细胞的影响。

结果

特发性PAH患者肺部的PA显示出脂质积累以及脂质稳态相关基因表达的改变。在PA平滑肌细胞中,外源性FFA导致PA内皮细胞过度增殖和内皮屏障功能障碍,这两者都是PAH的特征。在74例PH患者、30例无PH的疾病对照和65例健康对照的训练队列中,我们识别出了诊断和预后标志物,随后在一个独立队列中进行了验证。探索性分析显示PH患者的代谢组受到高度影响,机器学习证实了其具有很高的诊断潜力。我们得出了完全可解释的特定游离脂肪酸(FFA)/脂质比率,在训练队列中的曲线下面积(AUC)为0.89,在验证队列中为0.90,提供了出色的诊断准确性,优于机器学习结果。这些比率也具有预后价值,并补充了已确立的临床预后PAH评分(FPHR4p和COMPERA2.0),将它们的风险比(HR)分别从2.5和3.4显著提高到4.2和6.1。

结论

总之,我们的研究证实了脂质组改变在PH中的重要性,引入了创新的诊断和预后生物标志物。这些发现可能有潜力重塑PH的管理策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/942d187863e1/nihpp-2023.05.17.23289772v3-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/9338b121a3fa/nihpp-2023.05.17.23289772v3-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/b345cb6719a3/nihpp-2023.05.17.23289772v3-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/48f53d5093a0/nihpp-2023.05.17.23289772v3-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/890ca6b24bbb/nihpp-2023.05.17.23289772v3-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/2673134479e7/nihpp-2023.05.17.23289772v3-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/942d187863e1/nihpp-2023.05.17.23289772v3-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/9338b121a3fa/nihpp-2023.05.17.23289772v3-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/b345cb6719a3/nihpp-2023.05.17.23289772v3-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/48f53d5093a0/nihpp-2023.05.17.23289772v3-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/890ca6b24bbb/nihpp-2023.05.17.23289772v3-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/2673134479e7/nihpp-2023.05.17.23289772v3-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e6/10695261/942d187863e1/nihpp-2023.05.17.23289772v3-f0006.jpg

相似文献

1
Lipidomics for diagnosis and prognosis of pulmonary hypertension.脂质组学在肺动脉高压诊断和预后评估中的应用
medRxiv. 2023 Nov 29:2023.05.17.23289772. doi: 10.1101/2023.05.17.23289772.
2
Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension.用于肺动脉高压诊断和预后评估的脂质比率
Am J Respir Crit Care Med. 2025 Jul;211(7):1264-1276. doi: 10.1164/rccm.202407-1345OC.
3
AI-based Hepatic Steatosis Detection and Integrated Hepatic Assessment from Cardiac CT Attenuation Scans Enhances All-cause Mortality Risk Stratification: A Multi-center Study.基于人工智能的心脏CT衰减扫描检测肝脂肪变性及综合肝脏评估可增强全因死亡风险分层:一项多中心研究
medRxiv. 2025 Jun 11:2025.06.09.25329157. doi: 10.1101/2025.06.09.25329157.
4
Guanylate cyclase stimulators for pulmonary hypertension.用于肺动脉高压的鸟苷酸环化酶刺激剂。
Cochrane Database Syst Rev. 2016 Aug 2;2016(8):CD011205. doi: 10.1002/14651858.CD011205.pub2.
5
Carbon dioxide detection for diagnosis of inadvertent respiratory tract placement of enterogastric tubes in children.用于诊断儿童肠胃管意外置入呼吸道的二氧化碳检测
Cochrane Database Syst Rev. 2025 Feb 19;2(2):CD011196. doi: 10.1002/14651858.CD011196.pub2.
6
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
7
Direct-acting antivirals for chronic hepatitis C.用于慢性丙型肝炎的直接作用抗病毒药物。
Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143. doi: 10.1002/14651858.CD012143.pub3.
8
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.经胸多普勒超声心动图用于检测成人肺动脉高压。
Cochrane Database Syst Rev. 2022 May 9;5(5):CD012809. doi: 10.1002/14651858.CD012809.pub2.

本文引用的文献

1
The Impact of Abnormal Lipid Metabolism on the Occurrence Risk of Idiopathic Pulmonary Arterial Hypertension.异常脂质代谢对特发性肺动脉高压发病风险的影响。
Int J Mol Sci. 2023 Sep 19;24(18):14280. doi: 10.3390/ijms241814280.
2
Proline and glucose metabolic reprogramming supports vascular endothelial and medial biomass in pulmonary arterial hypertension.脯氨酸和葡萄糖代谢重编程支持肺动脉高压中的血管内皮和中膜生物量。
JCI Insight. 2023 Feb 22;8(4):e163932. doi: 10.1172/jci.insight.163932.
3
Metabolomic Signatures Associated With Pulmonary Arterial Hypertension Outcomes.
与肺动脉高压结局相关的代谢组学特征。
Circ Res. 2023 Feb 3;132(3):254-266. doi: 10.1161/CIRCRESAHA.122.321923. Epub 2023 Jan 4.
4
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.00879-2022. Print 2023 Jan.
5
Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension.从血浆蛋白质组中挖掘肺动脉高压分子病理学的见解。
Am J Respir Crit Care Med. 2022 Jun 15;205(12):1449-1460. doi: 10.1164/rccm.202109-2106OC.
6
Cohort profile: 'Biomarkers of Personalised Medicine' (BioPersMed): a single-centre prospective observational cohort study in Graz/Austria to evaluate novel biomarkers in cardiovascular and metabolic diseases.队列资料简介:“个体化医学的生物标志物”(BioPersMed):在格拉茨/奥地利的一项单中心前瞻性观察队列研究,旨在评估心血管和代谢疾病中的新型生物标志物。
BMJ Open. 2022 Apr 7;12(4):e058890. doi: 10.1136/bmjopen-2021-058890.
7
Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI.基于 4D 血流 MRI 的自动涡流血流法估测平均肺动脉压。
Magn Reson Imaging. 2022 May;88:132-141. doi: 10.1016/j.mri.2022.02.007. Epub 2022 Feb 18.
8
Severe Pulmonary Hypertension in COPD: Impact on Survival and Diagnostic Approach.慢性阻塞性肺疾病相关重度肺动脉高压:对生存的影响及诊断方法。
Chest. 2022 Jul;162(1):202-212. doi: 10.1016/j.chest.2022.01.031. Epub 2022 Jan 31.
9
Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.利用血浆蛋白质组学对肺动脉高压患者进行风险分层。
Am J Respir Crit Care Med. 2022 May 1;205(9):1102-1111. doi: 10.1164/rccm.202105-1118OC.
10
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.COMPERA 2.0:一种改良的肺动脉高压四层风险评估模型。
Eur Respir J. 2022 Jul 7;60(1). doi: 10.1183/13993003.02311-2021. Print 2022 Jul.